Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
05/25/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
448.45(c) 435.5(c) 419.4(c) 439.05(c) 436.25(c) Last
2 513 641 3 417 447 4 039 223 3 490 010 5 120 638 Volume
+0.21% -2.89% -3.70% +4.69% -0.64% Change
More quotes
Financials
Sales 2020 130 B 19 347 M 19 347 M
Net income 2020 41 652 M 6 207 M 6 207 M
Net cash position 2020 12 673 M 1 889 M 1 889 M
P/E ratio 2020 24,4x
Yield 2020 2,04%
Sales 2021 139 B 20 720 M 20 720 M
Net income 2021 46 850 M 6 982 M 6 982 M
Net cash position 2021 16 546 M 2 466 M 2 466 M
P/E ratio 2021 21,4x
Yield 2021 2,27%
Capitalization 1 019 B 152 B 152 B
EV / Sales 2020 7,75x
EV / Sales 2021 7,21x
Nbr of Employees 43 158
Free-Float 68,7%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
08/06Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
05/29NOVO NORDISK A/S : MIT - New technology enables fast protein synthesis
AQ
05/27NOVO NORDISK A/S : launches new social responsibility strategy to defeat diabete..
PU
05/25NOVO NORDISK A/S : – Share repurchase programme
AQ
05/21NOVO NORDISK : Goldman Sachs reiterates its Buy rating
MD
05/14NOVO NORDISK : UBS reiterates its Neutral rating
MD
05/14NOVO NORDISK : Receives a Buy rating from Goldman Sachs
MD
05/13NOVO NORDISK : JP Morgan gives a Buy rating
MD
05/13Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus pla..
GL
05/13NOVO NORDISK : JP Morgan remains its Buy rating
MD
05/12Ascendis Pharma A/S Will Appoint Jesper Hoiland as Global Chief Commercial Of..
AQ
05/12NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
AQ
05/11Novo Nordisk A/S
PU
05/11Novo Nordisk A/S
AQ
05/11NOVO NORDISK A/S : Share repurchase programme
PU
05/11NOVO NORDISK A/S : purchases B shares worth DKK 3,051 million from Novo Holdings..
AQ
More news
News in other languages on NOVO NORDISK A/S
05/29NOVO NORDISK A/S : MIT - New technology enables fast protein synthesis
05/27NOVO NORDISK A/S : launches new social responsibility strategy to defeat diabete..
05/25NOVO NORDISK A/S : – Share repurchase programme
05/21NOVO NORDISK : Goldman Sachs reste à l'achat
05/21NOVO NORDISK : Goldman Sachs reiterates its Buy rating
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK AS - 2019
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 432,38 DKK
Last Close Price 436,25 DKK
Spread / Highest target 20,3%
Spread / Average Target -0,89%
Spread / Lowest Target -33,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S13.55%152 053
JOHNSON & JOHNSON1.97%387 206
ROCHE HOLDING AG8.68%301 088
PFIZER, INC.-2.53%212 084
MERCK & CO., INC.-11.25%199 505
NOVARTIS AG-9.27%190 322